BiotechTube

OSI-906

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adrenocortical Carcinoma

Conditions

Adrenocortical Carcinoma

Trial Timeline

Dec 1, 2009 → Oct 8, 2012

NCT ID
NCT00924989

About OSI-906

OSI-906 is a phase 3 stage product being developed by Astellas Pharma for Adrenocortical Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00924989. Target conditions include Adrenocortical Carcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT00924989Phase 3Completed
NCT00514306Phase 1Completed
NCT00514007Phase 1Completed

Competing Products

6 competing products in Adrenocortical Carcinoma

See all competitors
ProductCompanyStageHype Score
DS9051bDaiichi SankyoPhase 1
33
Iressa (ZD1839)AstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52
BGG492NovartisPhase 2
52
SunitinibPfizerPhase 2
51
Relacorilant + PembrolizumabCorcept TherapeuticsPhase 1
28

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85